CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Clinical Study of the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung cancer-----a Prospective, Single-arm Exploratory Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04978753
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:05.089063+00:00
Published At: 2021-07-27T00:00:00+00:00
Record Updated At: 2021-07-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-small Cell Lung Cancer", "Brain Metastases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-07-27"
protocolSection.identificationModule.nctId: "NCT04978753"
protocolSection.identificationModule.officialTitle: "Phase II Clinical Study of the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung cancer-----a Prospective, Single-arm Exploratory Study"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.